San Francisco-based private equity firm Telegraph Hill Partners has gathered its largest fund to date and is looking to spend the $310 million raised on healthcare and life sciences companies that needs an extra push to make it big.
Formed in 2001, Telegraph Hill Partners focuses exclusively on life sciences and healthcare, and tends to invest in "companies with advanced technologies that have already demonstrated organic revenue growth and a superior business model."
Prior investments include PneumRx, which develops medical devices to assist in minimally invasive lung disease treatments; VidaCare, with its bone access platform; and LDR, which develops spinal implants.
THP said it offers a variety of investment structures, including venture capital, growth equity, buyouts and secondary acquisitions.
“Our team looks for managers who can demonstrate sustainable growth in the form of innovative product or service offerings, satisfied customers, efficient management processes and superior financial performance," according to the company’s website.